首页 > 最新文献

Medical Letter on Drugs and Therapeutics最新文献

英文 中文
In brief: Subcutaneous ocrelizumab (Ocrevus Zunovo) for multiple sclerosis. 简而言之治疗多发性硬化症的皮下注射奥克雷珠单抗(Ocrevus Zunovo)。
IF 1.4 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-28 DOI: 10.58347/tml.2024.1714b
{"title":"In brief: Subcutaneous ocrelizumab (Ocrevus Zunovo) for multiple sclerosis.","authors":"","doi":"10.58347/tml.2024.1714b","DOIUrl":"https://doi.org/10.58347/tml.2024.1714b","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":"66 1714","pages":"174"},"PeriodicalIF":1.4,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142513162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drugs for hepatitis C virus infection. 治疗丙型肝炎病毒感染的药物。
IF 1.4 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-28 DOI: 10.58347/tml.2024.1714a
{"title":"Drugs for hepatitis C virus infection.","authors":"","doi":"10.58347/tml.2024.1714a","DOIUrl":"https://doi.org/10.58347/tml.2024.1714a","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":"66 1714","pages":"169-174"},"PeriodicalIF":1.4,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142513159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Figure 1: Treatment of hepatitis C virus infection in treatment-naive adults. 图 1:治疗未接受治疗的成人丙型肝炎病毒感染。
IF 1.4 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-28 DOI: 10.58347/tml.2024.1714e
{"title":"Figure 1: Treatment of hepatitis C virus infection in treatment-naive adults.","authors":"","doi":"10.58347/tml.2024.1714e","DOIUrl":"https://doi.org/10.58347/tml.2024.1714e","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":"66 1714","pages":"e174"},"PeriodicalIF":1.4,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142513160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Table 3: Some drug interactions with DAAs for HCV infection. 表 3:与治疗 HCV 感染的 DAAs 的一些药物相互作用。
IF 1.4 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-28 DOI: 10.58347/tml.2024.1714f
{"title":"Table 3: Some drug interactions with DAAs for HCV infection.","authors":"","doi":"10.58347/tml.2024.1714f","DOIUrl":"https://doi.org/10.58347/tml.2024.1714f","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":"66 1714","pages":"e175"},"PeriodicalIF":1.4,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142513164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lazertinib (Lazcluze) for non-small cell lung cancer. 治疗非小细胞肺癌的 Lazertinib(Lazcluze)。
IF 1.4 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-28 DOI: 10.58347/tml.2024.1714g
{"title":"Lazertinib (Lazcluze) for non-small cell lung cancer.","authors":"","doi":"10.58347/tml.2024.1714g","DOIUrl":"https://doi.org/10.58347/tml.2024.1714g","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":"66 1714","pages":"e176-e177"},"PeriodicalIF":1.4,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142513163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addendum: Effectiveness of mRNA COVID-19 vaccines. 增编:mRNA COVID-19 疫苗的有效性。
IF 1.4 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-14 DOI: 10.58347/tml.2024.1713h
{"title":"Addendum: Effectiveness of mRNA COVID-19 vaccines.","authors":"","doi":"10.58347/tml.2024.1713h","DOIUrl":"10.58347/tml.2024.1713h","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":"66 1713","pages":"e168"},"PeriodicalIF":1.4,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drugs for plaque psoriasis. 治疗斑块状银屑病的药物。
IF 1.4 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-30 DOI: 10.58347/tml.2024.1712a
{"title":"Drugs for plaque psoriasis.","authors":"","doi":"10.58347/tml.2024.1712a","DOIUrl":"10.58347/tml.2024.1712a","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":"66 1712","pages":"153-160"},"PeriodicalIF":1.4,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142301220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Influenza vaccine for 2024-2025. 2024-2025 年流感疫苗。
IF 1.4 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-16 DOI: 10.58347/tml.2024.1711a
{"title":"Influenza vaccine for 2024-2025.","authors":"","doi":"10.58347/tml.2024.1711a","DOIUrl":"https://doi.org/10.58347/tml.2024.1711a","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":"66 1711","pages":"145-150"},"PeriodicalIF":1.4,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142301216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19 update: New Pfizer and Moderna vaccine formulations for 2024-2025. COVID-19 更新:辉瑞和 Moderna 2024-2025 年新疫苗配方。
IF 1.4 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-16 DOI: 10.58347/tml.2024.1711c
{"title":"COVID-19 update: New Pfizer and Moderna vaccine formulations for 2024-2025.","authors":"","doi":"10.58347/tml.2024.1711c","DOIUrl":"https://doi.org/10.58347/tml.2024.1711c","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":"66 1711","pages":"151-152"},"PeriodicalIF":1.4,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142301215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Roflumilast cream (Zoryve) for atopic dermatitis. 治疗特应性皮炎的罗氟司特乳膏(Zoryve)。
IF 1.4 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-16 DOI: 10.58347/tml.2024.1711b
{"title":"Roflumilast cream (Zoryve) for atopic dermatitis.","authors":"","doi":"10.58347/tml.2024.1711b","DOIUrl":"https://doi.org/10.58347/tml.2024.1711b","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":"66 1711","pages":"150-151"},"PeriodicalIF":1.4,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142301217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Medical Letter on Drugs and Therapeutics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1